RxDoctor Payments Data

Heather Kostoff, NP

Family · Corpus Christi, TXNPI 1568615318

Payments from drug & device makers

$10,217in general payments, 2019–2025

Across 492 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Lilly USA, LLC$2K
  • Nevro Corp.$910
  • AbbVie$746
  • AstraZeneca$450
  • Esperion Therapeutics, Inc.$404
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$10,183100%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,217 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$39,848
Medicare patients
90
Services billed
556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide142$141,181
TrulicityDulaglutide34$35,733
FarxigaDapagliflozin Propanediol44$33,500
JardianceEmpagliflozin22$27,186
MounjaroTirzepatide24$24,890
Repatha SureclickEvolocumab19$12,642
Janumet XrSitagliptin Phos/Metformin Hcl12$11,221
JanuviaSitagliptin Phosphate16$10,149
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$9,879
EliquisApixaban13$8,598
VascepaIcosapent Ethyl18$8,218
Icosapent Ethyl12$3,320
Levothyroxine Sodium245$2,808
Fluticasone Propionate99$1,980
Omega-3 Acid Ethyl Esters20$1,661

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,539$141,181142 claims
Lilly USA, LLCTrulicity, Mounjaro$1,844$60,62358 claims
AstraZenecaFarxiga$450$33,50044 claims
Boehringer IngelheimJardiance$135$27,18622 claims
MerckJanumet Xr, Januvia$18$21,37028 claims
PfizerEliquis$94$8,59813 claims
AbbVieSynthroid$746$1,14039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →